Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Fehse, Boris  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Ayuk F, Fehse B. CARs come to AID. Mol Ther. 2024.
Triviai I, Stübig T, Niebuhr B, Hussein K, Tsiftsoglou A, Fehse B, Stocking C, Kröger N. CD133 marks a stem cell population that drives human Primary Myelofibrosis. Haematologica. 2015.
Fischbach F, Richter J, Pfeffer LKristina, Fehse B, Berger SCarolina, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024.
Roh V, Abramowski P, Hiou-Feige A, Cornils K, Rivals J-P, Zougman A, Aranyossy T, Thielecke L, Truan Z, Mermod M, et al. Cellular Barcoding Identifies Clonal Substitution as a Hallmark of Local Recurrence in a Surgical Model of Head and Neck Squamous Cell Carcinoma. Cell Rep. 2018;25(8):2208-2222.e7.
Grochowska KM, Sperveslage M, Raman R, Failla AV, Głów D, Schulze C, Laprell L, Fehse B, Kreutz MR. Chaperone-mediated autophagy in neuronal dendrites utilizes activity-dependent lysosomal exocytosis for protein disposal. Cell Rep. 2023;42(8):112998.
Schwarze LIsabell, Głów D, Sonntag T, Uhde A, Fehse B. Correction: Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application. Gene Ther. 2022.
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger JS, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, et al. Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget. 2015;6(8):6341-6358.